奥西默替尼
临时的
肿瘤科
医学
中期分析
内科学
癌症
临床试验
腺癌
地理
ROS1型
考古
作者
Y-K. Shi,Dongqing Lv,Weineng Feng,Yan Yu,Shuyu Liu,Puyuan Xing,Junyi Zhang,Xiubao Ren,Jieyun Yin,Guang Han,Shundong Cang,Jie Chen,Meng Lv,En Chen,Yong Zhang
出处
期刊:ESMO open
[Elsevier]
日期:2024-03-01
卷期号:9: 102599-102599
标识
DOI:10.1016/j.esmoop.2024.102599
摘要
Osimertinib represents the current standard treatment for advanced EGFR-mutated NSCLC in the first-line (1L) setting. Acquired resistance inevitably occurs. The exploration of genomic profiles in resistant patients (pts) is vital.
科研通智能强力驱动
Strongly Powered by AbleSci AI